The American Diabetes Association and the European Association for the Study of Diabetes
convened a panel to update the prior position statements, published in 2012 and 2015, on …

Abstract Sodium–glucose cotransporter (SGLT) 2 inhibitors have been demonstrated to
reduce cardiovascular events, particularly heart failure, in cardiovascular outcome trials …

Cardiomyocytes exit the cell cycle and become terminally differentiated soon after birth.
Therefore, in the adult heart, instead of an increase in cardiomyocyte number, individual …

Abstract The American Diabetes Association and the European Association for the Study of
Diabetes convened a panel to update the prior position statements, published in 2012 and …

Heart failure and related morbidity and mortality are increasing at an alarming rate, in large
part, because of increases in aging, obesity, and diabetes mellitus. The clinical outcomes …

Coronary microvascular disease (CMD) refers to the subset of disorders affecting the
structure and function of the coronary microcirculation, is prevalent in patients across a …

Hypertension and type 2 diabetes are common comorbidities. Hypertension is twice as
frequent in patients with diabetes compared with those who do not have diabetes. Moreover …

Aims The expression of GADD153 (growth arrest and DNA damage-inducible gene 153), an
apoptosis-regulated gene, increases during endoplasmic reticulum (ER) stress. How …

Real-world studies have become increasingly important in providing evidence of treatment
effectiveness in clinical practice. While randomized clinical trials (RCTs) are the “gold …

Background Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration
of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly …